PT  - JOURNAL ARTICLE
AU  - Kim, Hyo Won
AU  - Kim, Inkee
AU  - Kim, Hyun Seung
AU  - Kim, Eun Chul
TI  - The comparison of handpiece anti-surge system and main body in cataract surgery
AID  - 10.1101/2023.10.18.23297207
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.18.23297207
4099  - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297207.short
4100  - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297207.full
AB  - Background/aims To compare the efficacy of the Centrion handpiece anti-surge system (Active Sentry®) and main body according to the grade of nucleosclerosis.Methods 600 eyes of 415 patients who underwent cataract surgery was retrospectively enrolled. Intraoperative parameters included phacoemulsification time (seconds), cumulative dissipated energy (CDE), and balanced salt solution (BSS) use (ml). Clinical measurements were made preoperatively and at one day, one month, two, and three months postoperatively, including the best corrected visual acuity (BCVA), and the corneal endothelial cell (CEC) count in the handpiece group (N=300) and main body group (N=300). Within the anti-surge group, the number of anti-surge system activated was collected.Results Anti-surge (times), phacoemulsification time, CDE, and BSS use significantly increased with increasing nucleosclerosis grades and in zonule weakness, poor mydriasis, and pseudoexfoliation syndrome in handpiece group, respectively (p < 0.05). Phacoemulsification time, CDE, and BSS use of handpiece group were significantly lower than those of main body group (p < 0.05). Phacoemulsification time, CDE, and CEC loss of handpiece group were significantly lower than those of main body group in nucleosclerosis grade 5 and 6 (p < 0.05). BSS uses of handpiece group were significantly lower than those of main body group in all nucleosclerosis grade (p < 0.05).Conclusion Because of the fast-reacting anti-surge, Intraoperative parameters were saved in handpiece anti-surge system rather than in main body. Therefore, the anti-surge system in the Centrion handpiece helps the surgeon perform safer cataract surgery in higher nucleosclerosis grade, zonule weakness, poor mydriasis, and pseudoexfoliation syndrome.Synopsis Anti-surge system in the Centrion handpiece helps the surgeon perform safer cataract surgery in higher nucleosclerosis grade, zonule weakness, poor mydriasis, and pseudoexfoliation syndrome.WHAT IS ALREADY KNOWN ON THIS TOPIC Active Sentry handpiece was reported to be as safe and efficacious as the Ozil handpiece, with the benefit of operating at lower intraocular pressure levelsWHAT THIS STUDY ADDS Anti-surge system in the Centrion handpiece helps the surgeon perform safer cataract surgery in higher nucleosclerosis grade, zonule weakness, poor mydriasis, and pseudoexfoliation syndrome.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY With anti-surge system in the Centrion handpiece, phacoemulsification can be performed effectively and safely in patients with complicated cataract.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2022R1F1A1069218) and Alcon through an Investigator Initiated Trial (IIT No. 73949933).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB)/Ethics Committee of Bucheon St. Mary Hospital approved this study protocol.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors